Infection of host tissue by pathogenic bacteria and/or stimulation by microbial components/virulence factors triggers the production of proinflammatory peptides that have the ability to activate and recruit neutrophilic polymorphonuclear leukocytes along a concentration gradient. Patients with periodontitis show increased numbers of neutrophils within periodontal tissues and pockets (
21), and recent work has demonstrated baseline hyperactivity of peripheral blood neutrophils, with respect to extracellular ROS release (
18) and proteolytic enzyme release (
9), in periodontitis patients relative to matched healthy controls. Such mechanisms when coactive may explain a significant amount of the oxidative stress reported in periodontitis-affected tissues (
6). Therefore, the influence of periodontal bacteria and their virulence factors on IL-8-mediated neutrophil chemotaxis and activation is important to elucidate. In contrast to biologically active IL-8
72aa, the IL-8
77aa peptide produced by epithelial cells, fibroblasts, and endothelial cells is resistant to a wide range of host proteinases; it has a low chemotactic activity (
10) and less respiratory burst-priming activity. In our experiments, we have used LPS as a positive control; LPS is a well-known chemotactic bacterial component which requires serum components such as LPS-binding protein for receptor activation (
28). However, as serum may also contain other chemotactic factors, it was excluded from our experiments, and the chemotactic activity of LPS in serum-free conditions here was greater than that of IL-8
77aa but less than that of IL-8
72aa toward primary neutrophils.
In this study, we have investigated a possible mechanism by which
P. gingivalis could manipulate IL-8 cytokine-mediated neutrophil chemotaxis using a dHL60 cell model and also primary human neutrophils. Gingipains increased the priming activity induced by IL-8
77aa on the fMLP-induced oxidative burst in primary neutrophils, data that confirm previous studies measuring elastase release from neutrophils, where IL-8
77aa-induced release was shown to be increased after gingipain treatment (
19).
Our results demonstrate a significant increase in the chemotactic properties of IL-8
77aa and a higher priming capability of IL-8
77aa after incubation with
l-cysteine-activated gingipains under the conditions described. Compared with primary neutrophils, dHL60 cells have low CXC2 receptor expression (
26), and this may explain the lower rate of dHL60 cell migration toward IL-8. The corresponding increase in data variation may account for the lack of significant increase in migration of dHL60 cells toward Rgp-treated IL-8
77aa compared to the increased migration of primary neutrophils. Chemotactic properties and priming abilities of truncated, gingipain-treated forms of IL-8
77aa were found to be two- to threefold higher than those of untreated IL-8
77aa. Using a neutralizing antibody against the complete sequence of IL-8, we confirmed that the increased biological activity of IL-8
77aa following gingipain treatment was due to the release of mature IL-8, rather than due to the release of small peptides identified by MS, as the neutralizing antibody (which does not recognize small peptide fragments) completely inhibited the increase in activity. Given that reported concentrations of reduced glutathione/cysteine in gingival fluids are 1,000-fold higher than those of serum (
7), this may represent a physiologically relevant mechanism whereby gingipains contribute to neutrophil recruitment and activation at
P. gingivalis-infected sites.
The extended amino terminus of IL-8
77aa folds back to interact with the essential Glu
4-Leu
5-Arg
6 (ELR) sequence; this may protect the ELR sequence from interaction with the receptor and may explain the low chemotactic activity of IL-8
77aa compared to IL-8
72aa. The N-terminal amino acid sequence of IL-8
77aa is AVLPRSAKELRCQCIKTYSK- (
21). Rgp has theoretical, specific amino peptidase cleavage activity at Arg
5-Ser
6 and Arg
11-Cys
12 (
15), yielding peptides with lengths of 72 and 66 aa. After Rgp treatment, we observed cleavage products of IL-8
77aa by MS/MS of the 5 and 11 aa corresponding to the putative N-terminal cleavage sites. There was no evidence of low-molecular-weight peptides corresponding to cleavage at the putative C-terminal sites. Even though some reports suggest that ELR sequences in IL-8 are necessary for high-affinity binding to IL-8 receptor, recent studies have shown that IL-8
66aa has similar activity to IL-8
72aa (
8). Our observations do not fully support the latter work: while an increase in activity of IL-8
77aa is observed after Rgp treatment, which results in products with lengths of 72 and 66 aa, a decrease in IL-8
72aa activity was observed after Rgp treatment, indicating that IL-8
66aa is not biologically active and that the observed increase in activity after treatment of IL-8
77aa with Rgp may be due to release of IL-8
72aa alone. Active IL-8 requires a properly folded protein structure with a highly conserved ELR sequence near the N terminus that is critical for its activity (
16). Kgp, with its specificity for the Lys-X peptide bond, is predicted to cleave the IL-8
77aa amino-terminal sequence at Lys
8-Glu
9, and this product was observed in our studies by MS/MS. The resultant 69-aa-long form of IL-8 shows enhanced biological activity compared with IL-8
77aa in our studies of chemotactic activity and respiratory burst priming. In contrast, the more biologically active form of IL-8
72aa showed reduced chemotactic activity after treatment with both Rgp and Kgp. Analysis of released peptides by MS/MS confirmed further cleavage of IL-8
72aa, releasing three peptides corresponding to the 15 N-terminal aa of IL-8
72aa. The presence of 5 aa at the N terminus of IL-8
77aa compared to IL-8
72aa appears to modulate cleavage of the peptide by gingipains. The difference in IL-8
77aa susceptibility to gingipain treatment compared with that of IL-8
72aa may relate to either differences in three-dimensional structures at the N terminus or specific charge differences which contribute to change in altered accessibility and thus cleavage by gingipains. Previous studies have shown that prolonged incubation with Rgp or Kgp could result total IL-8
77aa degradation (
19); physiologically, a concentration gradient will exist, where released gingipain will be highest in closest proximity to the site of bacterial colonization and via diffusion the concentration of gingipains will be lower further away from the site. Thus, while initial enzyme release may activate local IL-8
77aa in the early stages of infection, the IL-8
77aa variant may be completely degraded in the immediate locality over time. However, further from the site of infection, diffusing gingipain may cause activation of IL-8
77aa. The importance of this observation should be addressed in vivo following specific inhibition of gingipain activity or expression.
Previous studies have shown that the capacity of gingipains to manipulate the host cytokine network is partly due to degradation of other cytokines such as IL-1β, IL-6, and TNF-α (
3). Therefore, it has been suggested that the ability to inactivate cytokines by
P. gingivalis in the early stages of pathogenesis is advantageous for the organism. Rgp has recently been shown to digest secretory leukocyte protease inhibitor released from neutrophils, thus reducing the protective effect against bacterial proinflammatory molecules by which disease in periodontal tissues may be accelerated (
21). In contrast, degradation of proinflammatory cytokines could diminish neutrophil chemotaxis toward infected periodontal sites by lowering inflammatory cytokine secretion. However, in periodontal patients, neutrophil recruitment to the gingival crevice is maintained despite the presence of gingipains.
It is probable that an alternative mechanism exists to promote neutrophil chemotaxis and activity at periodontitis sites which may involve the secretion of the longer form of IL-877aa by nonimmune cells. This in vitro study provides a possible mechanism for P. gingivalis-manipulated neutrophil chemotaxis into periodontal pockets via activation of IL-877aa, as illustrated by Fig. . In conclusion, products from P. gingivalis may regulate host neutrophil accumulation at infected periodontal sites by initially stimulating the production of IL-877aa by nonimmune cells (e.g., epithelium) and promoting gingipain-dependent modification of IL-877aa into a more biologically active chemokine which promotes neutrophil chemotaxis and priming. Thereafter, after prolonged degradation by gingipains, the modified IL-877aa may reduce chemotaxis and neutrophil priming, thus prolonging the inflammatory lesion. Such a model (Fig. ) is worthy of further investigation.